Zenyaku Kogyo acquires exclusive rights in Japan to eblasakimab from ASLAN Pharma for the treatment of atopic dermatitis.
Zenyaku Kogyo has signed an exclusive license agreement to get secure eblasakimab, a monoclonal antibody being developed by Singapore-based biotech ASLAN Pharmaceuticals for the treatment of atopic dermatitis (AD)
Under the deal, ASLAN will grant Zenyaku Kogyo the rights to exclusively develop and commercialize the antibody, which targets the IL-13 receptor subunit of the Type 2 receptor, in Japan.
The Japanese company will now move onto its clinical development under the pact. The drug showed positive results in an overseas Phase Ib multiple-ascending-dose study that targeted moderate-to-severe AD. ASLAN is currently running a Phase IIb trial to test the drug in moderate-to-severe AD patients, with a topline readout scheduled for early July this year. ASLAN is also conducting an overseas PII study to investigate the drug in moderate-to-severe AD patients who have previously received dupilumab, with its data due out in the first quarter of 2024.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.